Category: naphthyridine

Atahan, Alparslan published the artcile1-Amino-2-hydroxy-4-naphthalenesulfonic acid based Schiff bases or naphtho[1,2-d]oxazoles: Selective synthesis and photophysical properties, Formula: C10H9NO4S, the publication is Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy (2015), 61-67, database is CAplus and MEDLINE.

A series of Schiff base and naphtho[1,2-d]oxazole derivatives were selectively synthesized via condensation reaction of 1-amino-2-hydroxy-4-naphthalenesulfonic acid and benzaldehyde derivatives at same conditions. The synthesized compounds were then characterized by using ¹HNMR, ¹³CNMR, FTIR spectroscopies and elemental analyses. It was seen that the Schiff bases e. g., I, generated in the presence of OH group at ortho position of benzaldehyde derivatives However, the products were naphtho[1,2-d]oxazoles e. g., II, in other cases. Then, the synthesized compounds were photophys. investigated by UV absorption and fluorescence emission spectroscopies. As a result, these Schiff bases have shown long wavelength absorption (λ_max: 386 nm) and emission (λ_max: 429-437 nm) effect while synthesized naphtho[1,2-d]oxazole derivatives have a set of absorption (λ_max: about 296, 308, 320 nm) and emission maxima (λ_max: 378-395 nm) at lower wavelength.

Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy published new progress about 116-63-2. 116-63-2 belongs to naphthyridine, auxiliary class Sulfonic acid,Amine,Naphthalene,Alcohol,Organic Pigment, name is 4-Amino-3-hydroxynaphthalene-1-sulfonic acid, and the molecular formula is C10H9NO4S, Formula: C10H9NO4S.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Whitehead, Clark M. published the artcileExisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival, Computed Properties of 59973-80-7, the publication is Molecular Cancer Therapeutics (2003), 2(5), 479-488, database is CAplus and MEDLINE.

We reported previously a significant increase in survival of nude rats harboring orthotopic A549 human non-small cell lung cancer tumors after treatment with a combination of exisulind (Sulindac Sulfone) and docetaxel (D. C. Chan, Clin. Cancer Res., 8: 904-912, 2002). The purpose of the current study was to determine the biochem. mechanisms responsible for the increased survival by an anal. of the effects of both drugs on A549 orthotopic lung tumors and A549 cells in culture. Orthotopic A549 rat lung tissue sections from drug-treated rats and A549 cell culture responses to exisulind and docetaxel were compared using multiple apoptosis and proliferation analyses [i.e., terminal deoxynucleotidyl transferase-mediated nick end labeling, active caspase 3, the caspase cleavage products cytokeratin 18 and p85 poly(ADP-ribose) polymerase, and Ki-67]. Immunohistochem. was used to determine cGMP (cGMP) phosphodiesterase (PDE) expression in tumors. The cGMP PDE composition of cultured A549 cells was resolved by DEAE-Trisacryl M chromatog. and the pharmacol. sensitivity to exisulind, and addnl. known PDE inhibitors were determined by enzyme activity assays. Exisulind inhibited A549 cell cGMP hydrolysis and induced apoptosis of A549 cells grown in culture. PDE5 and 1 cGMP PDE gene family isoforms identified in cultured cells were highly expressed in orthotopic tumors. The in vivo apoptosis rates within the orthotopic tumors increased 7-8-fold in animals treated with the combination of exisulind and docetaxel. Exisulind increased the in vivo apoptosis rates as a single agent. Docetaxel, but not exisulind, decreased proliferative rates within the tumors. The data indicate that exisulind-induced apoptosis contributed significantly to the increased survival in rats treated with exisulind/docetaxel. The mechanism of exisulind-induced apoptosis involves inhibition of cGMP PDEs, and these results are consistent with a cGMP-regulated apoptosis pathway.

Molecular Cancer Therapeutics published new progress about 59973-80-7. 59973-80-7 belongs to naphthyridine, auxiliary class Immunology/Inflammation,COX, name is Sulindac sulfone, and the molecular formula is C6H12O2, Computed Properties of 59973-80-7.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Tarkuc, Simge published the artcileThe relationship between molecular structure and electronic properties in dicyanovinyl substituted acceptor-donor-acceptor chromophores, Name: 9,10-Diethynylanthracene, the publication is Tetrahedron (2017), 73(33), 4994-5004, database is CAplus.

In this contribution the authors describe a combined exptl. and theor. study of the relation between the mol. structure and the electronic properties of conjugated donor-acceptor type chromophores for light-harvesting applications. A series of model systems was synthesized where a central anthracene (electron donor) is connected to dicyanovinyl units (electron acceptor) through a π-conjugated spacer. The study of the redox and optical properties of these chromophores and of reference compounds without dicyanovinyl units allows the authors correlate the electronic properties to the presence of the electron withdrawing groups and the mol. conformation. Comparison with calculated electronic structure shows that the construction of chromophores that consist of electron donating and accepting units does not always follow the simple rules that are generally used in the design of such mols. The results show a subtle relation between the charge transfer character and the geometry of the mols. In some cases this leads to significant contribution of charge transfer excitation to the absorption spectra of some chromophores while such contributions are completely absent in others.

Tetrahedron published new progress about 18512-55-5. 18512-55-5 belongs to naphthyridine, auxiliary class Alkynyl,Anthracene, name is 9,10-Diethynylanthracene, and the molecular formula is C16H14O6, Name: 9,10-Diethynylanthracene.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Nortcliffe, Andrew published the artcileSynthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment, Safety of Sulindac sulfone, the publication is Bioorganic & Medicinal Chemistry (2014), 22(2), 756-761, database is CAplus and MEDLINE.

A series of analogs of the non-steroidal anti-inflammatory drug (NSAID) sulindac were synthesized tethered to nitric oxide (NO) donating functional groups. Sulindac shows antiproliferative effects against immortal PC3 cell lines. It was previously demonstrated that the effect can be enhanced when tethered to NO releasing groups such as nitrate esters, furoxans and sydnonimines. To explore this approach further, a number of sulindac-NO analogs were prepared and they were evaluated as NO-releasing cytotoxic agents against prostate cancer (PCa) cell lines. Compounds (I) and (II) exhibited significant cytotoxic with IC₅₀ values of 6.1±4.1 and 12.1±3.2 μM, resp., coupled with observed nitric oxide release.

Bioorganic & Medicinal Chemistry published new progress about 59973-80-7. 59973-80-7 belongs to naphthyridine, auxiliary class Immunology/Inflammation,COX, name is Sulindac sulfone, and the molecular formula is C20H17FO4S, Safety of Sulindac sulfone.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Abu-Dief, Ahmed M. published the artcileTargeting ctDNA binding and elaborated in-vitro assessments concerning novel Schiff base complexes: Synthesis, characterization, DFT and detailed in-silico confirmation, Formula: C10H9NO4S, the publication is Journal of Molecular Liquids (2021), 114977, database is CAplus.

Two novel complexes for Zn²⁺ and VO²⁺ ions, were prepared from tridentate dibasic chelating Schiff base ligand. 1-((3,5-di-tert-butyl-2-hydroxybenzylidene)amino)naphthalen-2-ol-5-sodium sulfonate (DSHN), was the ligand used in this study. Alternative spectral tools were applied to elucidate structural composition of new compounds Also, geometry optimization for all synthesizes was conducted by Gaussian09 program via DFT method, to obtain optimal structures and essential parameters. Moreover, the biochem. behavior for all synthesizes, was explored based on tested reactivity against various microbial strains and cancer cells (HCT-116, MCF-7, and HepG-2). The two complexes exhibited interestingly anti-proliferative potential against human cancer cell lines. The antioxidant behavior of the two complexes was studied by DPPH and SOD assays. Particularly, Zn(II) and VO(II) complexes presented more enhanced antimicrobial and anticancer features compared to the free ligand (DSHN), with superiority for VO(II) complex. The binding nature of two complexes with calf thymus DNA (ctDNA), was examined by various methods as, spectrophotometry, viscosity and gel electrophoresis. Their binding efficiency with ctDNA was proposed to be just intercalation or replacement mode. This in-vitro assay was confirmed by in-silico simulation vs. 1cca, 1jnx, 1smp, 2 h80 and 5ajh as the co-crystals for selected pathogen-proteins, which attribute to microbes and cancer cells.

Journal of Molecular Liquids published new progress about 116-63-2. 116-63-2 belongs to naphthyridine, auxiliary class Sulfonic acid,Amine,Naphthalene,Alcohol,Organic Pigment, name is 4-Amino-3-hydroxynaphthalene-1-sulfonic acid, and the molecular formula is C10H9NO4S, Formula: C10H9NO4S.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Eissa, Ibrahim H. published the artcileDesign and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors, Quality Control of 116-63-2, the publication is Anti-Cancer Agents in Medicinal Chemistry (2018), 18(2), 195-209, database is CAplus and MEDLINE.

Backgroun/Methods: In attempt to develop new potent antitumor agents, a series of quinoxaline derivatives was designed and synthesized. The novel compounds were tested in vitro for their antiproliferative activities against HePG2, MCF7 and HCT116 cell lines. Addnl., DNA binding affinities as well as DNAtop II inhibitory activities of the synthesized compounds were investigated as potential mechanism for anticancer activity. Compounds 13, 15, 16 and 19 exhibited good cytotoxicity activities against the three cell lines (IC50 ranging from 7.6 to 32.4 muM) comparable to that of doxorubicin (IC50 = 9.8 muM). Results: Interestingly, the results of DNA binding and DNAtop II inhibition assays were in agreement with those of the cytotoxicity tests, where the most potent anticancer compounds showed good DNA binding affinities (IC50 ranging from 25.1 to 32.4 muM) and DNAtop II inhibitory activities (IC50 ranging from 6.4 to 15.3 muM) comparable to those of doxorubicin (IC50 = 28.1 and 3.8 muM, resp.). Furthermore, mol. docking studies were carried out for the new compounds in order to investigate their binding pattern with the prospective target, DNAtop II complex (PDBcode: 3qx3).

Anti-Cancer Agents in Medicinal Chemistry published new progress about 116-63-2. 116-63-2 belongs to naphthyridine, auxiliary class Sulfonic acid,Amine,Naphthalene,Alcohol,Organic Pigment, name is 4-Amino-3-hydroxynaphthalene-1-sulfonic acid, and the molecular formula is C10H9NO4S, Quality Control of 116-63-2.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Noser, Ahmed A. published the artcileSynthesis, in silico and in vitro assessment of new quinazolinones as anticancer agents via potential AKT inhibition, Computed Properties of 116-63-2, the publication is Molecules (2020), 25(20), 4780, database is CAplus and MEDLINE.

A series of novel quinazolinone I [ R = 4-carboxyphenyl, 3-carboxyphenyl, 4-hexadecoxycarbonylphenyl, etc.] was synthesized and examined for their cytotoxicity to HepG2, MCF-7, and Caco-2 in an MTT assay. Among these derivatives, compounds I [ R = 4-hexadecoxycarbonylphenyl] and I [ R = (2-methylbutanoyl)oxyphenyl] exhibited significant cytotoxic activity against Caco-2, HepG2, and MCF-7 cancer cells. Compound I [ R = 4-hexadecoxycarbonylphenyl] had more significant inhibitory effects than compound I [ R = (2-methylbutanoyl)oxyphenyl] on Caco-2, HepG2, and MCF-7 cell lines, with IC₅₀ values of 23.31 ± 0.09, 53.29 ± 0.25, and 72.22 ± 0.14μM, resp. The AKT pathway was one of human cancer’s most often deregulated signals. AKT was also overexpressed in human cancers such as glioma, lung, breast, ovarian, gastric, and pancreas. A mol. docking study was performed to analyze the inhibitory action of newly synthetic quinazolinone derivatives against Homo sapiens AKT1 protein. Mol. docking simulations were found to be in accordance with in-vitro studies, and hence supported the biol. activity. The results suggested that compounds I [ R = 4-hexadecoxycarbonylphenyl] and I [ R = (2-methylbutanoyl)oxyphenyl] could be used as drug candidates for cancer therapy via its potential inhibition of AKT1 as described by docking study.

Molecules published new progress about 116-63-2. 116-63-2 belongs to naphthyridine, auxiliary class Sulfonic acid,Amine,Naphthalene,Alcohol,Organic Pigment, name is 4-Amino-3-hydroxynaphthalene-1-sulfonic acid, and the molecular formula is C10H9NO4S, Computed Properties of 116-63-2.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Sinibaldi, Victoria J. published the artcilePhase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma, Quality Control of 59973-80-7, the publication is American Journal of Clinical Oncology (2006), 29(4), 395-398, database is CAplus and MEDLINE.

Objectives: In this phase II study, the combination of docetaxel and exisulind (a GMP phosphodiesterase inhibitor) was given to patients with metastatic androgen independent prostate cancer (AIPC) to establish efficacy, assess toxicity, and determine pharmacokinetics of docetaxel administered alone and in combination with exisulind. Methods: Fourteen patients with metastatic AIPC were registered to receive weekly docetaxel for 4 wk, followed by 2 wk of rest; repeated up to a maximum of 6 cycles. Exisulind 250 mg was given orally twice a day starting on day 8 of the study and taken continuously. Results: All patients were evaluable for toxicity, response and survival. Grade 3 reversible toxicities included: fatigue, nausea, diarrhea, abdominal pain, rash, syncope, pulmonary edema, deep vein thrombosis, congestive heart failure, and elevations in transaminases, requiring therapy delays and/or dose reductions, or removal from therapy. Only 3 out of 14 patients (21.4%) had a 50% decline in prostate specific antigen (PSA) level that lasted â‰? wk; 1 out of 14 patients (7%) had a lymph node response. Median survival was 17.28 mo. Docetaxel pharmacokinetics for 11 patients demonstrated mean ± SD clearance values that were similar during week 1 and week 3 when exisulind had been added. Conclusions: Overall, our trial indicated that the toxicity profile and efficacy of this regimen is unlikely to be substantially better than single agent docetaxel.

American Journal of Clinical Oncology published new progress about 59973-80-7. 59973-80-7 belongs to naphthyridine, auxiliary class Immunology/Inflammation,COX, name is Sulindac sulfone, and the molecular formula is C10H10O2, Quality Control of 59973-80-7.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Garcia-Gonzalez, Ma. Carmen published the artcilePairing multicomponent stators with aromatic rotators for new emissive molecular rotors, SDS of cas: 18512-55-5, the publication is Organic & Biomolecular Chemistry (2021), 19(15), 3404-3412, database is CAplus and MEDLINE.

We demonstrate here that the Ugi-Sonogashira protocol can be successfully used to obtain five new mol. rotors such as I with strong emission. The mol. rotors have been synthesized by combining multicomponent stators derived from Ugi reactions of 4-iodoaniline, trans-cinnamaldehyde, 2-bromobenzoic acid, and cyclohexyl or tert-Bu isonitriles with dialkyne axles with phenylene, p-xylene, naphthalene and anthracene linkers. The synthesized conjugated rotors are highly fluorescent (Φ_f = 0.39 to Φ_f = 0.10), and changes in their emission were observed upon variations of the surrounding media, particularly on changes in solvents leading to aggregation or on increases in solvent viscosity.

Organic & Biomolecular Chemistry published new progress about 18512-55-5. 18512-55-5 belongs to naphthyridine, auxiliary class Alkynyl,Anthracene, name is 9,10-Diethynylanthracene, and the molecular formula is C18H10, SDS of cas: 18512-55-5.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem

Chang, Wen-Chi L. published the artcileSulindac sulfone is most effective in modulating β-catenine-mediated transcription in cells with mutant APC, Application of Sulindac sulfone, the publication is Annals of the New York Academy of Sciences (2005), 41-55, database is CAplus and MEDLINE.

Sulindac sulfone (FGN-1, Aptosyn), a metabolite of the nonsteroidal anti-inflammatory drug sulindac, lacks cyclooxygenase inhibitory activity. Although its ability to inhibit tumorigenesis in both carcinogen-treated animals and patients with familial adenomatous polyposis has been attributed to the induction of apoptosis, its complete mechanism of action remains unclear. The purpose of the present study was to determine the ability of sulindac metabolites to regulate cellular levels of β-catenin and downstream targets of the adenomatous polyposis coli (APC)/β-catenin pathway in vitro. Sulindac sulfone was consistently more potent than the sulfide metabolite in all analyses, significantly decreasing the expression of total cellular β-catenin (50% of control), pro-caspase 3 (49%), cyclin D1 (51%), and PPARδ (65%) in SW480 cells. No significant alteration in pro-caspase 3 or β-catenin expression was found in HCA7, LS174, or Caco-2 cells treated with sulindac sulfone. A dose-dependent reduction in TCF-mediated transcriptional activity was also observed in SW480 cells. These data demonstrate that sulindac sulfone can modulate the APC/β-catenin pathway in vitro and that its efficacy is dependent upon the mutational status of APC and β-catenin.

Annals of the New York Academy of Sciences published new progress about 59973-80-7. 59973-80-7 belongs to naphthyridine, auxiliary class Immunology/Inflammation,COX, name is Sulindac sulfone, and the molecular formula is C20H17FO4S, Application of Sulindac sulfone.

Referemce:
https://en.wikipedia.org/wiki/1,8-Naphthyridine,
1,8-Naphthyridine | C8H6N2 – PubChem